ArticleRadiation oncology (London, England)2016
Portfolio of prospective clinical trials including brachytherapy: an analysis of the ClinicalTrials.gov database.
Article in Radiation oncology (London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 18 citations in OpenAlex.
- Review of brachytherapy clinical trials: a cross-sectional analysis of ClinicalTrials.gov.Radiation oncology (London, England) · 2024Review
- Rise of Clinical Studies in the Field of Machine Learning: A Review of Data Registered in ClinicalTrials.gov.International journal of environmental research and public health · 2021Review
- Obstacles to the reuse of study metadata in ClinicalTrials.gov.Scientific data · 2020Article
- Clinical trials involving positron emission tomography and prostate cancer: an analysis of the ClinicalTrials.gov database.Radiation oncology (London, England) · 2018Article
- A single institution analysis of low-dose-rate brachytherapy: 5-year reported survival and late toxicity outcomes.Journal of contemporary brachytherapy · 2018Review
- Clinical Research Informatics: Supporting the Research Study Lifecycle.Yearbook of medical informatics · 2017Review
- Current status and perspectives of interventional clinical trials for glioblastoma - analysis of ClinicalTrials.gov.Radiation oncology (London, England) · 2017Review
- Model assessment of individual tumor control rate and adverse effects in comparing locally advanced cervical cancer treatment using intracavitary with and without interstitial brachytherapy.Journal of contemporary brachytherapy · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo evaluate the current status of prospective interventional clinical trials that includes brachytherapy (BT) procedures.
methodsThe records of 175,538 (100 %) clinical trials registered at ClinicalTrials.gov were downloaded on September 2014 and a database was established. Trials using BT as an intervention were identified for further analyses. The selected trials were manually categorized according to indication(s), BT source, applied dose rate, primary sponsor type, location, protocol initiator and funding source. We analyzed trials across 8 available trial protocol elements registered within the database.
resultsIn total 245 clinical trials were identified, 147 with BT as primary investigated treatment modality and 98 that included BT as an optional treatment component or as part of the standard treatment. Academic centers were the most frequent protocol initiators in trials where BT was the primary investigational treatment modality (p < 0.01). High dose rate (HDR) BT was the most frequently investigated type of BT dose rate (46.3 %) followed by low dose rate (LDR) (42.0 %). Prostate was the most frequently investigated tumor entity in trials with BT as the primary treatment modality (40.1 %) followed by breast cancer (17.0 %). BT was rarely the primary investigated treatment modality for cervical cancer (6.8 %).
conclusionMost clinical trials using BT are predominantly in early phases, investigator-initiated and with low accrual numbers. Current investigational activities that include BT mainly focus on prostate and breast cancers. Important questions concerning the optimal usage of BT will not be answered in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.